Last reviewed · How we verify
Continuous Docetaxel
Continuous docetaxel is a taxane chemotherapy agent that stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division.
Continuous docetaxel is a taxane chemotherapy agent that stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.
At a glance
| Generic name | Continuous Docetaxel |
|---|---|
| Sponsor | University of Turin, Italy |
| Drug class | Taxane (microtubule stabilizer) |
| Target | β-tubulin / microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel is a semi-synthetic taxane derived from the Pacific yew tree that binds to microtubule-associated proteins and β-tubulin, promoting microtubule assembly and inhibiting disassembly. This leads to cell cycle arrest in the G2/M phase and apoptosis. The 'continuous' formulation refers to an extended or continuous dosing schedule rather than the standard intermittent regimen, potentially improving efficacy or tolerability.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Prostate cancer
- Gastric cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Fatigue
- Nausea/vomiting
- Diarrhea
- Alopecia
- Hypersensitivity reactions
Key clinical trials
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
- A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (PHASE3)
- Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) (PHASE3)
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (PHASE3)
- Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (PHASE2)
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) (PHASE1)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous Docetaxel CI brief — competitive landscape report
- Continuous Docetaxel updates RSS · CI watch RSS
- University of Turin, Italy portfolio CI